False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
Interpretation
PET
PSMA
Pitfall
Radiotherapy
Recurrence
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
03
04
2020
accepted:
28
06
2020
pubmed:
19
8
2020
medline:
29
5
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Readers need to be informed about potential pitfalls of [ Here we report [ Consensus reads were false positive in 20 regions of 17/217 (8%) patients with lesion validation. Majority of the false positive interpretations (13 of 20, 65%) occurred in the context of suspected prostate (bed) relapse (T) after radiotherapy (n = 11); other false positive findings were noted for prostate bed post prostatectomy (T, n = 2), pelvic nodes (N, n = 2), or extra pelvic lesions (M, n = 5). Major sources of false positive findings were PSMA-expressing residual adenocarcinoma with marked post-radiotherapy treatment effect. False negative interpretation occurred in 8 regions of 6/79 (8%) patients with histopathology validation, including prostate (bed) (n = 5), pelvic nodes (n = 1), and extra pelvic lesions (n = 2). Lesions were missed mostly due to small metastases or adjacent bladder/urine uptake. [ ClinicalTrials.gov Identifiers: NCT02940262 and NCT03353740.
Identifiants
pubmed: 32808077
doi: 10.1007/s00259-020-04945-1
pii: 10.1007/s00259-020-04945-1
pmc: PMC7835157
mid: NIHMS1661784
doi:
Substances chimiques
Edetic Acid
9G34HU7RV0
Banques de données
ClinicalTrials.gov
['NCT02940262', 'NCT03353740']
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
501-508Subventions
Organisme : NCI NIH HHS
ID : R01 CA212148
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229354
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA235741
Pays : United States
Investigateurs
Okamoto Shozo
(O)
Louise Emmett
(L)
Helle D Zacho
(HD)
Harun Ilhan
(H)
Christoph Rischpler
(C)
Axel Wetter
(A)
Heiko Schoder
(H)
Irene A Burger
(IA)
Références
J Med Imaging Radiat Oncol. 2017 Dec;61(6):739-744
pubmed: 28623852
J Urol. 2015 Oct;194(4):983-8
pubmed: 25963190
Cancer. 2009 Feb 1;115(3):673-9
pubmed: 19117039
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Eur Urol Focus. 2018 Sep;4(5):686-693
pubmed: 28753806
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):355-67
pubmed: 10974448
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
Arch Pathol Lab Med. 2007 Mar;131(3):360-71
pubmed: 17516739
Cancer Imaging. 2017 Dec 21;17(1):31
pubmed: 29268784
J Nucl Med. 2017 Oct;58(10):1617-1623
pubmed: 28408531
Cancer. 1997 Jan 1;79(1):81-9
pubmed: 8988730
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Mod Pathol. 2018 Jan;31(S1):S110-121
pubmed: 29297495
Theranostics. 2017 Apr 10;7(6):1770-1780
pubmed: 28529650
J Urol. 2019 Jun;201(6):1127-1133
pubmed: 30741847
BMC Cancer. 2019 Jan 7;19(1):18
pubmed: 30616601
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
Cancer Treat Rev. 2016 Jul;48:50-60
pubmed: 27347670